(Q38075061)

28 August 2017

1 reference

title

Current options for the treatment of Helicobacter pylori (English)

1 reference

28 August 2017

0 references

Sotirios D Georgopoulos

series ordinal

1

1 reference

28 August 2017

Vasilios Papastergiou

series ordinal

2

1 reference

28 August 2017

Stylianos Karatapanis

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

211-223

1 reference

Helicobacter pylori public health implications

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Hypergastrinemia is associated with increased risk of distal colon adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori treatment in the era of increasing antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

H pylori antibiotic resistance: prevalence, importance, and advances in testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori therapy demystified

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

"Rescue" regimens after Helicobacter pylori treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Pylera for the eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

The importance of efflux pumps in bacterial antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

The status of antimicrobial resistance of Helicobacter pylori in eastern Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Should quinolones come first in Helicobacter pylori therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Modified sequential therapy regimens for Helicobacter pylori eradication: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Rescue Therapy for Helicobacter pylori Infection 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.763926

10.1517/14656566.2013.763926

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference